Translate Bio to Participate in Upcoming Investor Conferences
12 November 2020 - 11:30PM
Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA)
therapeutics company developing a new class of potentially
transformative medicines to treat or prevent debilitating or
life-threatening diseases, today announced that the Company will
participate in the following upcoming investor conferences:
- Jefferies Virtual London Healthcare
Conference: John Schroer, chief financial
officer, will present a corporate overview at the Jefferies Virtual
London Healthcare Conference on Wednesday, November 18, 2020 at
7:55 a.m. ET.
- Evercore ISI HealthCONx
Conference: Ronald Renaud, chief
executive officer, will participate in a fireside chat at the
Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020
at 2:15 p.m. ET.
A live webcast of the sessions will be accessible
through the “Events and Presentations” page of the Company's
website at investors.translate.bio. A replay of the webcasts will
be archived on the Translate Bio’s website for 30 days following
the presentation.
About Translate BioTranslate Bio
is a clinical-stage mRNA therapeutics company developing a new
class of potentially transformative medicines to treat diseases
caused by protein or gene dysfunction, or to prevent infectious
diseases by generating protective immunity. Translate Bio is
primarily focused on applying its technology to treat pulmonary
diseases caused by insufficient protein production or where the
reduction of proteins can modify disease. Translate Bio’s lead
pulmonary candidate is being evaluated as an inhaled treatment for
cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional
pulmonary diseases are being evaluated in discovery-stage research
programs that utilize a proprietary lung delivery platform.
Translate Bio believes that mRNA can be delivered to target tissues
via multiple routes of administration and, consequently, its
technology may apply broadly to a wide range of diseases, including
diseases that affect the liver. Translate Bio is also pursuing the
development of mRNA vaccines for infectious diseases under a
collaboration with Sanofi Pasteur.
Contacts for Translate Bio |
|
|
Investors Teri
Dahlmantdahlman@translate.bio617-817-8655 |
MediaMaura
Gavaghanmgavaghan@translate.bio617-233-1154 |
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024